These findings suggest that targeting TLR9 and the cGAS-STING pathway may be a promising approach for developing new drugs against DCM, while IL-37 could serve as a therapeutic option for treating patients with DCM. Here, TLR9 is linked to familial dilated cardiomyopathy.